Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 418-431

  Yang, Hanseul ^a   Lee, Sungsu ^a   Lee, Seungjoo ^a   Kim, Kangsan ^a   Yang, Yeseul ^a   Kim, Jeong Hoon ^b   Adams, Ralf H ^c,d   Wells, James M ^e   Morrison, Sean J ^f   Koh, Gou Young ^a   Kim, Injune ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b University of Ulsan   (South Korea)

^c Max Plank Institute for Molecular Biomedicine   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CISPLATIN; TRANSCRIPTION FACTOR SOX17; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC MODEL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LEWIS CARCINOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HMGB PROTEINS; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; SOXF TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84873843115     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64547     Document Type: Article

References (48)

1. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6): 417-427.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5): 646-674.
3. Koh YJ, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010;18(2): 171-184.
4. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011; 27: 563-584.
5. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011; 17(7): 347-362.
6. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8): 592-603.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3): 232-239.
8. Paez-Ribes M, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3): 220-231.
9. Casanovas O. The adaptive stroma joining the antiangiogenic resistance front. J Clin Invest. 2011; 121(4): 1244-1247.
10. Kappel A, Ronicke V, Damert A, Flamme I, Risau W, Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood. 1999;93(12): 4284-4292.
11. Suchting S, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007;104(9): 3225-3230.
12. Murakami M, et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121(7): 2668-2678.
13. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6): 769-778.
14. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. Suppression of Notch signalling by the COUPTFII transcription factor regulates vein identity. Nature. 2005;435(7038): 98-104.
15. Lee D, et al. ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel progenitor specification. Cell Stem Cell. 2008;2(5): 497-507.
16. Gerhardt H, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6): 1163-1177.
17. Mazzone M, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136(5): 839-851.
18. Eilken HM, Adams RH. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol. 2010;22(5): 617-625.
19. Felcht M, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122(6): 1991-2005.
20. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell. 2002;3(2): 167-170.
21. Kanai-Azuma M, et al. Depletion of definitive gut endoderm in Sox17-null mutant mice. Development. 2002;129(10): 2367-2379.
22. Spence JR, et al. Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Dev Cell. 2009;17(1): 62-74.
23. Kim I, Saunders TL, Morrison SJ. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell. 2007;130(3): 470-483.
24. Burtscher I, Barkey W, Schwarzfischer M, Theis FJ, Lickert H. The Sox17-mCherry fusion mouse line allows visualization of endoderm and vascular endothelial development. Genesis. 2011;50(6): 496-505.
25. Matsui T, et al. Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. J Cell Sci. 2006; 119(pt 17): 3513-3526.
26. Bilguvar K, et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet. 2008;40(12): 1472-1477.
27. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6): 610-621.
28. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8): 911-920.
29. Shojaei F, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16): 6742-6747.
30. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8): 610-622.
31. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6): 464-478.
32. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med. 2002;8(12): 563-571.
33. Hamzah J, et al. Vascular normalization in Rgs5- deficient tumours promotes immune destruction. Nature. 2008;453(7193): 410-414.
34. Goel S, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3): 1071-1121.
35. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10(3): 165-177.
36. Mazzieri R, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19(4): 512-526.
37. Cooke VG, et al. Pericyte depletion results in hypoxia- associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21(1): 66-81.
38. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994; 367(6463): 576-579.
39. Inai T, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1): 35-52.
40. Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One. 2012;7(1):e28305.
41. Miao Z, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A. 2007;104(40): 15735-15740.
42. Sawamiphak S, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010;465(7297): 487-491.
43. Wang Y, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010; 465(7297): 483-486.
44. Sinner D, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007;27(22): 7802-7815.
45. Chew LJ, et al. SRY-box containing gene 17 regulates the Wnt/beta-catenin signaling pathway in oligodendrocyte progenitor cells. J Neurosci. 2011; 31(39): 13921-13935.
46. He S, Kim I, Lim MS, Morrison SJ. Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes Dev. 2011;25(15): 1613-1627.
47. Park KS, Wells JM, Zorn AM, Wert SE, Whitsett JA. Sox17 influences the differentiation of respiratory epithelial cells. Dev Biol. 2006;294(1): 192-202.
48. Sun JF, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102(1): 128-133.